• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 3, Issue 5
  3. Authors

Online ISSN: 2515-8260

Volume3, Issue5

VEGF mimic peptides: Potential applications in central nervous system therapeutics

    Lucia De Rosa Luca Domenico D'Andrea Luca Domenico D'Andrea Luca Domenico D'Andrea Mauro Cataldi Luca Domenico D'Andrea

European Journal of Molecular & Clinical Medicine, 2017, Volume 3, Issue 5, Pages 233-251

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

VEGF is expressed in central nervous system and its expression increases in hypoxia and in inflammatory brain disorders. A wealth of data suggests that VEGF may exert neuroprotective activities and promote neuroregeneration in disease status. Moreover, the risk of developing certain neurological disorders may be dependent on dysfunction in the VEGF system. Therefore, a strong rationale does exist to suggest that VEGF-based therapeutics could be implemented in conditions such as stroke or amyotrophic lateral sclerosis and experimental data supporting this hypothesis have been obtained. However, the unfavorable pharmacokinetic profile of this growth factor, and concerns on its safety have limited the development of VEGF as a therapeutic tool for neurological disorders. In this review, we discuss why a new class of VEGF-mimic peptides holds promises to become a safer, cheaper and more easily manageable tool for central nervous system therapeutics. Focal Points ● Bench: The analysis of the effects of small peptides reproducing one or more regions of VEGF may help understanding basic issues on the structure-activity relationship of this growth factor. ● Bedside: Small VEGF-mimic peptides could have better pharmacokinetic and/or toxicological properties than VEGF and be, therefore, potentially suitable for use in human diseases. ● Community: VEGF-mimic peptides-based therapeutics could help reducing the burden of severe neurodegenerative disorders that cannot be efficiently treated with currently available drugs.
Keywords:
  • PDF (1060 K)
  • XML
(2017). VEGF mimic peptides: Potential applications in central nervous system therapeutics. European Journal of Molecular & Clinical Medicine, 3(5), 233-251.
Lucia De Rosa; Luca Domenico D'Andrea; Luca Domenico D'Andrea; Luca Domenico D'Andrea; Mauro Cataldi; Luca Domenico D'Andrea. "VEGF mimic peptides: Potential applications in central nervous system therapeutics". European Journal of Molecular & Clinical Medicine, 3, 5, 2017, 233-251.
(2017). 'VEGF mimic peptides: Potential applications in central nervous system therapeutics', European Journal of Molecular & Clinical Medicine, 3(5), pp. 233-251.
VEGF mimic peptides: Potential applications in central nervous system therapeutics. European Journal of Molecular & Clinical Medicine, 2017; 3(5): 233-251.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 8
  • PDF Download: 19
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  info@ejmcm.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

Editorial Team:  editor@ejmcm.com

For Special Issue Proposal : chiefeditor.ejmcm@gmail.com / info@ejmcm.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus